GenSight Biologics to Participate in Multiple Conferences in November
Paris, France, November 6, 2017, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that members of its management team will participate in several industry, medical and investor conferences.
Chief Financial Officer
+33 (0)1 76 21 72 20
+33 (0)1 44 71 98 55
Source: GenSight Biologics